MedPath

Providing a therapeutic method for regeneration of damaged bone tissue in the oral and maxillofacial region by mononuclear cells isolated from the patient's own fat tissue

Not Applicable
Conditions
Patients with maxillofacial bone defects.
Hypertrophy of bone
M89.3
Registration Number
IRCT20181205041860N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
20
Inclusion Criteria

The patient has a bone defect in the maxillofacial region

Exclusion Criteria

The defect should not be socket, dehiscence, fenestration, and also sinus not involved.
systemic and metabolic diseases
active infection
compromised immune system
pregnant and or lactating women
osteoporosis and osteopetrosis
previous alveolar surgery
smoking

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
In this study, safety is the main primary outcome. Timepoint: The patient will be visited one and six days as well as 1 and 6 months after surgery. But during this time, if patients have any abnormal clinical symptoms, you will be counseled or visited by telephone or in person. Method of measurement: To evaluate the safety, different parameters such as infection, inflammation, fibrosis tissue formation, local edema, local erythema, pain, dental implant rejection, dental sensitivity, and mortality will be evaluated through clinical evaluations, blood tests, CT scans Conical scans and scatological analyzes.
Secondary Outcome Measures
NameTimeMethod
ew bone formation. Timepoint: after 6 months from surgery. Method of measurement: analysis of Cone Beam-CT data and histology images.
© Copyright 2025. All Rights Reserved by MedPath